Stratos Wealth Advisors LLC Raises Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Stratos Wealth Advisors LLC increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 21.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 117,721 shares of the biopharmaceutical company’s stock after buying an additional 20,628 shares during the quarter. Stratos Wealth Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $2,748,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Rothschild Investment LLC lifted its stake in Catalyst Pharmaceuticals by 1,085.7% during the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,520 shares during the period. Advisory Services Network LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at $39,000. Quarry LP acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter worth $40,000. Financial Life Planners acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter worth $42,000. Finally, Bessemer Group Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 331.4% during the third quarter. Bessemer Group Inc. now owns 3,486 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 2,678 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CPRX has been the subject of a number of research reports. Citigroup boosted their target price on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Zacks Research raised Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Finally, Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Three equities research analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Strong Buy” and a consensus price target of $34.00.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $24.69 on Friday. The firm has a fifty day moving average price of $24.10 and a 200 day moving average price of $22.86. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $26.58. The stock has a market cap of $3.02 billion, a P/E ratio of 14.61, a P/E/G ratio of 0.72 and a beta of 0.67.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).